A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07670416

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07670416
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07670416. Randomized; double masking; primary purpose treatment. Start 2026-07-03 (actual); primary completion 2028-02-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Condition
Obesity
Condition
Overweight
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Combination product)
Enicepatide
Intervention (Combination product)
Placebo
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct07670416
Content hash
d1976cbab366d8d5f3e90079015cc05a77a1f95767e9d5f494860ab7b55798ef